Drug Inspectors Mandated to Ramp Up Inspections Amid Compliance Lapses

Madhubani, Bihar – In a bid to strengthen regulatory oversight in the pharmaceutical sector, authorities in Madhubani district have reissued strict guidelines requiring drug inspectors to conduct a minimum of 20 routine inspections and 5 joint surprise raids every month. The directive comes in response to observed lapses in enforcement, including delays in drug licensing and recurring violations at sales outlets.

According to local health department officials, the renewed instructions aim to address inconsistencies uncovered during a recent audit of the Online Drug Licensing System (ONDLS). Inspectors have been reminded that failure to meet these targets could lead to further scrutiny, as some personnel have reportedly fallen short in their duties.

Key Enforcement Measures Outlined

The guidelines, which were originally circulated but now reiterated for emphasis, include several critical operational requirements:
  • Monthly Inspection Quota: Each drug inspector must perform at least 20 standard inspections of pharmaceutical establishments and 5 collaborative surprise checks or raids, involving coordination with other regulatory teams.
  • Action on Repeat Violations: If similar errors—such as improper storage, labeling issues, or unlicensed sales—are detected multiple times at the same outlet, inspectors are empowered to initiate immediate corrective actions. A mandatory report of these steps must be forwarded to the Deputy Drug Controller for oversight.
  • Expedited Licensing Process: Reviewing officers are directed to fast-track applications for new drug licenses, which have previously been stalled for 20-25 days. This bottleneck has delayed license issuances and hampered business operations for legitimate vendors.
  • Detailed Reporting Standards: All inspection reports must now include comprehensive details, such as the full name and address of the pharmaceutical sales establishment, along with the proprietor’s email address (where available), to enhance traceability and follow-up.
These measures are part of a broader push to ensure public safety and compliance with national drug control standards under the Drugs and Cosmetics Act. Officials noted that the pharmaceutical trade in Madhubani, a key district in Bihar’s cosmetics and herbal medicine hub, has seen a surge in outlets, necessitating more vigilant monitoring.
While specific names of issuing officials were not disclosed in the directive, sources within the district’s drug control wing emphasized that the guidelines stem from a high-level review of enforcement data. “The goal is not just to meet numbers but to prevent risks to consumers from substandard or counterfeit drugs,” one anonymous regulator stated.
As Bihar continues to grapple with counterfeit drug challenges, this initiative in Madhubani could serve as a model for other districts. Health experts predict that consistent implementation could reduce violation rates by up to 30% within the next quarter.

Related Posts

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

New Delhi: Alembic Pharmaceuticals has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Levothyroxine Sodium Tablets USP in…

STF busts fake meds racket spread across 6 states

Dehradun: Uttarakhand special task force (STF) on Friday busted an online fake medicine racket operating through a Facebook page that allegedly sold counterfeit drugs, including cancer medicines, at discounts of…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

STF busts fake meds racket spread across 6 states

STF busts fake meds racket spread across 6 states

All the Way from Teeth to Tee: Hole in One

All the Way from Teeth to Tee: Hole in One

Zydus Lifesciences Q4FY26 net profit rises 9%

Zydus Lifesciences Q4FY26 net profit rises 9%

Chemists strike on May 20: Reasons behind today’s all-India strike

Chemists strike on May 20: Reasons behind today’s all-India strike

AbbVie loses patent plea for Hep C drug

AbbVie loses patent plea for Hep C drug